Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Chloroquine

- PMLiVE

Pfizer and BioNTech speak out against CureVac suit over patents for COVID-19 vaccines

The civil suit claims that once CureVac had withdrawn its vaccine candidate, the company was unable to garner 50% efficacy in a late-stage trial

- PMLiVE

Fauci addresses need for pan-coronavirus and intranasal vaccines to combat COVID-19 variants

Vaccine manufacturers have been urged to move forward with producing Omicron-targeting formulations

Trust and transparency in Pharma & healthcare: impact of the COVID-19 pandemic

While it is obvious that trust in life science and healthcare companies is suboptimal, exactly how to improve the public’s trust is unclear...

Impetus Digital

- PMLiVE

WHO updates COVID-19 vaccination strategy to reach unprotected populations

The update raises targets to vaccinate 100% of healthcare workers and 100% of the highest risk populations with primary and booster doses

- PMLiVE

Gilead’s COVID-19 drug Veklury recommends for approval by CHMP

If approved by the EC, Veklury will become the only direct-acting antiviral with full marketing authorisation in the EU

- PMLiVE

Biopharma industry launches Berlin Declaration to ensure equal access during future pandemics

The Declaration outlines a framework that could help to ensure that lower-income countries receive pandemic vaccines and treatments

- PMLiVE

COVID-19 pandemic ‘reversed’ progress made in fight against antimicrobial resistance in US, new CDC report reveals

The report concluded that resistant hospital-onset infections and deaths both increased at least 15% during the first year of the pandemic

- PMLiVE

Elsevier launches global collaboration to ‘navigate’ changing landscape of scientific research

The initiative will examine the increased public attention on science during the COVID-19 pandemic and its impact on the academic research community

- PMLiVE

FDA grants Novavax’s COVID-19 vaccine emergency use authorisation for adults

The decision was based on data from a phase 3 trial which showed the vaccine was 90.4% effective in preventing mild, moderate or severe COVID-19

- PMLiVE

NHS awarded George Cross for efforts shown during the COVID-19 pandemic

The George Cross is the UK’s highest civilian gallantry award and has only been given to a collective group twice before

- PMLiVE

Expert review shows AstraZeneca’s COVID-19 vaccine is ‘equally effective’ as mRNA vaccines

The study informs policymakers about the optimal deployment of COVID-19 vaccines over the next 12 months

- PMLiVE

UK study reveals Omicron variant ‘substantially less likely’ to cause long Covid

The new study by King’s College London found that the odds of experiencing long COVID were between 20-50% less during the Omicron period versus the Delta period

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links